文献速递银屑病与炎症性皮肤病

伊克珠单抗治疗慢性斑块状银屑病2期研究开放标签治疗4年以上的疗效与安全性

Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2018-04-10

这项2期试验的开放标签扩展研究分析了伊克珠单抗120mg后80mg每4周皮下注射治疗慢性斑块状银屑病的4年疗效与安全性。开放标签扩展第208周时,82%患者达到银屑病面积和严重程度指数评分改善75%,64%患者静态医生总体评估评分为0或1,45%评分为0。疗效可维持长达4年,16.7%患者发生严重不良事件。

要点

  • 开放标签扩展第208周时,82%患者达到PASI 75改善。
  • 第208周时64%患者sPGA评分为0或1,45%评分为0。
  • 16.7%患者发生严重不良事件,87%患者发生1种或以上治疗中出现的不良事件。

核心结论

  • 伊克珠单抗治疗慢性斑块状银屑病的疗效可维持长达4年。

研究设计与样本

  • 该研究为2期试验的开放标签扩展研究,采用末次观测值结转法分析。
  • 患者先接受伊克珠单抗120mg,随后80mg皮下注射,每4周一次。
  • 完成随机安慰剂对照试验的患者中93%进入开放标签扩展研究。

主要发现

  • 开放标签扩展第208周时,82%患者报告银屑病面积和严重程度指数评分改善75%。
  • 第208周时,64%患者静态医生总体评估评分为0或1,45%患者评分为0。
  • 与基线相比,患者皮肤病生活质量指数和瘙痒视觉模拟量表评分下降。
  • 其他疗效和健康结局指标也观察到改善。
  • 16.7%患者发生严重不良事件,87%患者发生1种或以上治疗中出现的不良事件,3例患者发生严重感染,1例患者报告2次主要心血管事件。

局限性

  • 该研究为开放标签研究,缺乏安慰剂或活性对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ixekizumab has demonstrated improvement in patients with moderate-to-severe psoriasis by selectively targeting interleukin-17A, which is a proinflammatory cytokine that is important in the pathogenesis of psoriasis. OBJECTIVE: To report 4-year efficacy and safety results from the open-label extension (OLE) of this phase 2 trial. METHODS: Analysis was by last observation carried forward. Patients received ixekizumab, 120 mg, and then 80 mg subcutaneously once every 4 weeks. RESULTS: Of the patients who completed the randomized placebo-controlled trial, 93% entered the OLE. A 75% reduction in the Psoriasis Area Severity Index score was reported in 82% of patients at week 208 of the OLE. A static Physician's Global Assessment score of 0 or 1 was reported in 64% of patients, and a score of 0 was reported in 45% at week 208. Patients' Dermatology Life Quality Index and Itch Visual Analog Scale scores decreased when compared with baseline. Improvements were observed in other efficacy and health outcome measures. Serious adverse events were observed in 16.7% of patients, and 87% had 1 or more treatment-emergent adverse events. Three patients had serious infections. One patient reported 2 major cardiovascular events. LIMITATIONS: The study was unblinded and lacked a placebo or active comparator. CONCLUSIONS: Efficacy was shown to be maintained for up to 4 years of ixekizumab treatment.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Zachariae C, Gordon K, Kimball AB, et al. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018. PMID: 29653208. doi:10.1016/j.jaad.2018.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。